Skip to content

comparison of dexmedetomidine-remifentanil versus propofol-remifentanil for monitored anesthesia care during pancreatic extraorporeal shock wave lithotripsy

comparison of dexmedetomidine-remifentanil versus propofol-remifentanil for monitored anesthesia care during pancreatic extraorporeal shock wave lithotripsy

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072641
Enrollment
Unknown
Registered
2023-06-20
Start date
2023-06-20
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic duct stones

Interventions

Dexmedetomidine-Remifentanil group:Use a combination of dexmedetomidine and remifentanil as a sedation strategy
Propofol-Remifentanil group:Use a combination of propofol and remifentanil as a sedation strategy

Sponsors

Bian Jinjun
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1) age =18 years old and =65 years old; ASA I ~ II 2) patients undergoing the first elective pancreatic extracorporeal shock wave lithotripsy under intravenous anesthesia 3) Patients voluntarily participated and signed informed consent

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1) obese (BMI=28kg/m2) and predicted difficult airway, such as limited mouth opening, Mallampati score =3 and cervical spine inactivity 2) History of respiratory insufficiency or sleep apnea 3) long-term use of painkillers 4) allergy to the included anesthetic drugs

Design outcomes

Primary

MeasureTime frame
Incidence of respiratory related adverse events;

Secondary

MeasureTime frame
Incidence rate of adverse events related to circulation;VAS rating;MOAA/S rating;The incidence of sedation requiring propofol supplementation;Patient satisfaction with sedation regimen;

Countries

China

Contacts

Public ContactJinjun Bian

Changhai Hospital

jinjunbicu@163.com+86 136 0196 3321

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026